Oxford Instruments Share News (OXIG)

Oxford Instruments, which supplies tools for industry and research, said its varied portfolio helped it weather the economic downturn as it reported higher profits for the year to March 31. Adjusted pre-tax profits climbed to £11.1m from £9.5m the previous year on revenue that climbed to £206.5m from £176.5m."It is difficult to predict the impact and duration of the current economic downturn but we have taken extensive management action to ensure that we are well positioned to meet our targets as markets improve. Trading so far in the current year has been in line with our expectations," said chairman Nigel Keen.Losses at pharma group Renovo rose to £8.7m, from £7.35m in the half year to March, with sales up a touch to £4.1m. Cash burn was £12.6m, up from £12m. "Our key focus continues to be the progression of our lead product, Juvista, through the European Phase 3 programme.The first Phase 3 trial in scar revision surgery is currently recruiting patients across nine countries and is on track to report in the first half of 2011," Renovo said. Cash at end March totalled £73m.FTSE TechMARK - FallersVislink (VLK) 26.00p -9.57%E2V Technologies (E2V) 68.00p -6.85%Oxford Instruments (OXIG) 138.00p -6.76%Inion (IIN) 0.71p -5.33%Corin Group (CRG) 56.00p -5.08%Phytopharm (PYM) 5.25p -4.55%Alizyme (AZM) 6.00p -4.00%Ark Therapeutics (AKT) 44.50p -3.26%Triad Group (TRD) 31.50p -3.08%Skyepharma (SKP) 170.00p -2.72%FTSE TechMARK - RisersOxford Biomedica (OXB) 12.00p +6.67%Emblaze (BLZ) 37.00p +6.47%Trafficmaster (TFC) 31.50p +5.00%Renovo Group (RNVO) 28.75p +4.55%AEA Technology (AAT) 23.00p +4.55%Puricore (PURI) 13.75p +3.77%Xaar (XAR) 83.00p +3.75%Redstone (RED) 8.50p +3.03%Innovation Group (TIG) 10.00p +2.56%NCC Group (NCC) 360.00p +2.13%